Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 54, 5368-5373, October 15, 1994]
© 1994 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Graaf, W. T. A.
Right arrow Articles by Mulder, N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Graaf, W. T. A.
Right arrow Articles by Mulder, N. H.

Effects of Amiodarone, Cyclosporin A, and PSC 833 on the Cytotoxicity of Mitoxantrone, Doxorubicin, and Vincristine in Non-P-glycoprotein Human Small Cell Lung Cancer Cell Lines1

Winette T. A. van der Graaf2, Elisabeth G. E. de Vries, Hetty Timmer-Bosscha, Gert Jan Meersma, Geert Mesander, Edo Vellenga and Nanno H. Mulder

Divisions of Medical Oncology [W. T. A. v. d. G., E. G. E. d. V., H. T-B., G. J. M., N. H. M.], Clinical Immunology [G. M.], and Hematology [E. V.], Department of Internal Medicine, University Hospital, Oostersingel 59, 9713 EZ Groningen, The Netherlands

The multidrug resistance (MDR) modulators amiodarone (AM), cyclosporin A (CsA), and PSC 833 were tested for their potential to modulate cytotoxicity of doxorubicin (DOX), vincristine (VCR), and mitoxantrone (MX) in a sensitive human small cell lung carcinoma cell line GLC4, in its DOX-resistant non-P-glycoprotein subline GLC4-Adr, and in its cisplatin-resistant subline GLC4-CDDP. GLC4-Adr, in which overexpression of the so-called multidrug resistance-associated protein has been demonstrated, is 91-fold resistant for DOX, 22-fold for VCR, and 7.5-fold for MX, compared with its sensitive cell line. AM previously modulated DOX and VCR resistance in the P-glycoprotein-positive human colon cancer cell line COLO 320. Cytotoxicity was studied in the microtiter well tetrazolium assay. In the small cell lung carcinoma cell lines described above, AM did not increase cytotoxicity of DOX, but increased VCR cytotoxicity; moreover, AM was shown to be a potent modulator of MX cytotoxicity. CsA did not potentiate DOX cytotoxicity, but, at a concentration of 4 µM, it modestly increased VCR cytotoxicity in GLC4. However, 0.8 and 4.0 µM CsA protected against MX cytotoxicity in GLC4 and GLC4-CDDP, but no effect was observed in GLC4-Adr. At the much higher ID10 concentration CsA modulated MX cytotoxicity 1.6-fold in GLC4-Adr and slightly in GLC4 and GLC4-CDDP. PSC 833, a nonimmunosuppressive CsA analogue, did not alter the cytotoxicity of DOX or MX in these cell lines, but potentiated VCR cytotoxicity in GLC4-Adr at a concentration of 0.4 µM. The modulation of MX cytotoxicity by AM and the protection by CsA was confirmed in a clonogenic assay. In the colony-forming unit granulocytemonocyte assay, no additional MX toxicity on normal bone marrow by AM was observed. Flow cytometry of cellular MX fluorescence was performed in order to elucidate the mechanism behind the AM-induced increased MX cytotoxicity. This revealed an increase in cellular MX after 1-h incubation of MX combined with AM and an inhibition of efflux from GLC4 and GLC4-Adr; CsA and PSC 833 had no effect on MX efflux. An increase in MX-induced cleavable complexes by AM in GLC4 was observed using the K+/sodium dodecyl sulfate coprecipitation assay, but no effect of CsA was found. In conclusion, AM enhances MX and VCR cytotoxicity in these sensitive, non-P-glycoprotein DOX and cisplatin-resistant small cell lung carcinoma cell lines. It also inhibits efflux of MX and causes more MX-induced cleavable complexes.

1 This work was supported in part by Dutch Cancer Society Grant GUKC 91-12.

2 To whom requests for reprints should be addressed.

Received 4/21/93. Accepted 8/17/94.




This article has been cited by other articles:


Home page
BloodHome page
R. B. Walter, J. L. Pirga, M. R. Cronk, S. Mayer, F. R. Appelbaum, and D. E. Banker
PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism
Blood, November 15, 2005; 106(10): 3584 - 3593.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Kornmann, K. D. Danenberg, N. Arber, H. G. Beger, P. V. Danenberg, and M. Korc
Inhibition of Cyclin D1 Expression in Human Pancreatic Cancer Cells Is Associated with Increased Chemosensitivity and Decreased Expression of Multiple Chemoresistance Genes
Cancer Res., July 1, 1999; 59(14): 3505 - 3511.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. D. Smith and X. Zhang
Mechanism of Action of Cryptophycin
J. Biol. Chem., March 15, 1996; 271(11): 6192 - 6198.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1994 by the American Association for Cancer Research.